CEO, AgomAb Therapeutics
AgomAb Therapeutics is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. In April 2019, a 21 million euros financing round was raised. Prior to AgomAb Therapeutics, Tim was VP Corporate Development at AM-Pharma where he was responsible for Corporate and Business Development of the company. In that capacity he co-led the $600M option-to-acquisition deal between Pfizer and AM-Pharma. Prior to that, Tim was a senior associate at Aescap Venture, a venture capital fund investing in European medical companies, where he was instrumental in the financing and support of various portfolio companies. Tim holds an executive MBA from IMD (Switzerland), where he was named Valedictorian, and gained a Science and Innovation Masters and a Drug Innovation Masters, both with honors from Utrecht University (NL).
Hans van Leeuwen